Arvinas, Inc. (ARVN)

Market Cap	835.66M -35.9%
Revenue (ttm)	262.60M -0.3%
Net Income	-80.80M
EPS	-1.14
Shares Out	63.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	222,315
Open	13.28
Previous Close	13.30
Day's Range	13.04 - 13.46
52-Week Range	5.90 - 18.93
Beta	1.88
Analysts	Buy
Price Target	15.57 (+18.31%)
Earnings Date	Feb 24, 2026

About ARVN

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, suc...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 27, 2018
• Employees: 430
• Stock Exchange: NASDAQ
• Ticker Symbol: ARVN
• Website: https://www.arvinas.com

Financial Performance

In 2025, Arvinas's revenue was $262.60 million, a decrease of -0.30% compared to the previous year's $263.40 million. Losses were -$80.80 million, -59.38% less than in 2024.

Analyst Summary

According to 21 analysts, the average rating for ARVN stock is "Buy." The 12-month stock price target is $15.57, which is an increase of 18.31% from the latest price.

Price Target

$15.57

(18.31% upside)

Analyst Consensus: Buy